← Back to Clinical Trials
Recruiting NCT07004140

Proving Utility of a New Field-cycling MRI Prototype in Acute Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Stroke Acute
Sponsor University of Aberdeen
Study Type OBSERVATIONAL
Phase N/A
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-09-16
Completion 2026-05
Interventions
3T MRI research scanField-Cycling Imaging research scanFollow up 3T MRI research scan

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can show changes in the brain within the first day of a stroke due to a blocked blood vessel or bleeding in the brain. The main question it aims to answer is: • Can FCI identify brain tissue that might recover within the first few hours after a stroke begins? Participants will undergo a standard MRI scan and an FCI scan, as soon as possible after hospital admission. Participants who have had a blocked blood vessel will also provide a blood sample and will have a follow up visit at 30 days for repeat of both scans and providing another blood sample.

Eligibility Criteria

Inclusion Criteria: * Acute stroke (\<24 hours from symptom onset). * NIHSS ≥4 and \<25 with cortical involvement and/or large vessel occlusion on baseline imaging. * Able to undergo 3T and FCI MRI \<24h of onset. * With or without thrombolysis. Exclusion Criteria: * Contraindications to MRI. * Medically unstable. * Unable to comprehend or comply with instructions regarding scanning * Prior mRS of \>3. * Identified for thrombectomy. * Non-stroke pathology or previous cortical infarct on CT scan \> 1/3 of middle cerebral artery territory.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}